Valneva SE (VALN)
| Market Cap | 1.38B |
| Revenue (ttm) | 134.54M |
| Net Income (ttm) | -78.53M |
| Shares Out | 48.94M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $28.15 |
| Previous Close | $27.55 |
| Change ($) | 0.60 |
| Change (%) | 2.18% |
| Day's Open | 28.48 |
| Day's Range | 28.11 - 28.61 |
| Day's Volume | 3,062 |
| 52-Week Range | 24.16 - 31.33 |
Saint- Herblain ( France) and New York, NY , July 19 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic...
The FDA grants Breakthrough Therapy Designation to Valneva SE's (NASDAQ: VALN) single-shot chikungunya vaccine candidate, VLA1553. This new U.S. milestone comes in addition to the FDA Fast Track designa...
Saint- Herblain (France), July 6 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infect...
Saint Herblain ( France), July 5 , 2021 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infecti...
Saint- Herblain (France), July 1 , 2021 – Following a media article published yesterday, Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and comme...
Saint - Herblain ( France), June 23 , 2021 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for in...
These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on ...
Here's a list of seven global stocks that can be added to the portfolio for exposure to growth themes from different regions. The post 7 Global Stocks That Are Worth Adding to Your Portfolio appeared fi...
Saint-Herblain (France) – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...
Saint-Herblain (France), May 5, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...
Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...
Valneva SE has filed to go public with an IPO on the NASDAQ.
Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month.
About VALN
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities... [Read more...]
| Industry Biotechnology | IPO Date May 6, 2021 |
| CEO Thomas Lingelbach | Employees 500 |
| Stock Exchange NASDAQ | Ticker Symbol VALN |
Financial Performance
In 2020, Valneva's revenue was 110.32 million, a decrease of -12.58% compared to the previous year's 126.20 million. Losses were -64.39 million, 3,592.3% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for Valneva is 35.25, which is an increase of 25.22% from the latest price.